3-(2-isobutoxy-5-(4-isobutoxybenzoyl)phenyl)propionic acid | 269082-09-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-isobutoxy-5-(4-isobutoxybenzoyl)phenyl)propionic acid
• 英文别名: 3-[2-Isobutoxy-5-(4-isobutoxybenzoyl)phenyl]propionic acid；3-[2-(2-methylpropoxy)-5-[4-(2-methylpropoxy)benzoyl]phenyl]propanoic acid
• CAS: 269082-09-9
• 化学式: C₂₄H₃₀O₅
• 分子量: 398.499
• InChiKey: IXOKIWZMTKUQKC-UHFFFAOYSA-N

物化性质

• 熔点：
  102-103 °C(Solv: dichloromethane (75-09-2); hexane (110-54-3))
• 沸点：
  563.0±50.0 °C(Predicted)
• 密度：
  1.109±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  29
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(2-isobutoxy-5-(4-isobutoxybenzoyl)phenyl)propionic acid 在 草酰氯 、 N,N-二甲基甲酰胺 、 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 以94%的产率得到3-[2-Isobutoxy-5-(4-isobutoxy-benzoyl)-phenyl]-propionamide
  参考文献：
  名称：

  Discovery of Nonpeptidic Small-Molecule AP-1 Inhibitors:  Lead Hopping Based on a Three-Dimensional Pharmacophore Model

  摘要：

  We designed and synthesized small-molecule activator protein-1 (AP-1) inhibitors based on a three-dimensional (3D) pharmacophore model that we had previously derived from a cyclic decapeptide exhibiting AP-1 inhibitory activity. New AP-1 inhibitors with a 1-thia-4-azaspiro[4.5]decane or a benzophenone scaffold, which inhibit the DNA-binding and transactivation activities of AP-1, were discovered using a "lead hopping" procedure. An additional investigation of the benzophenone analogues confirmed the reliability of the pharmacophore model, its utility to discover AP-1 inhibitors, and the potency of the benzophenone derivatives as a lead series.

  DOI：

  10.1021/jm050550d
• 作为产物：
  描述：

  6-甲基香豆素 在 盐酸 、 manganese(IV) oxide 、 sodium chlorite 、 甲烷磺酸 、 四磷十氧化物 、 硫酸 、 5%-palladium/activated carbon 、 sodium formate 、 potassium carbonate 、 溶剂黄146 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 氯苯 、 异丙醇 为溶剂， 反应 16.75h， 生成 3-(2-isobutoxy-5-(4-isobutoxybenzoyl)phenyl)propionic acid
  参考文献：
  名称：

  一种4,4'-二取代二苯甲酮类化合物及其制备方 法

  摘要：

  本发明提供了一类4，4′‑二取代二苯甲酮类化合物，具有下列式I所示的结构：该化合物能够很好地抑制AP‑1蛋白和NDM‑1蛋白的活性，其针对NDM‑1蛋白的IC50值为52.93±11.86μM。

  公开号：

  CN103183606B

文献信息

• NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF
  申请人：Chaki Hisaaki

  公开号：US20090118169A1

  公开（公告）日：2009-05-07

  A compound comprising the atom corresponding to N 3 and the two or more atoms selected from N 1 , N 2 , N 4 and N 5 , said atoms constitute the pharmacophore represented by the following formula: wherein N 1 represents an atom to which a donative hydrogen atom in a hydrogen-bond donating group is bonded or a hydrogen-bond accepting atom in a hydrogen-bond accepting group; N 3 represents a hydrogen-bond accepting atom in a hydrogen-bond accepting group; and N 2 , N 4 and N 5 independently represents an arbitrary carbon atom constituting a hydrophobic group and defined by the interatomic distances between N 1 , N 2 , N 3 , N 4 and N 5 ; and, in the optimized three-dimensional structure thereof, the distances between the atom corresponding to N 3 and the two or more atoms selected from N 1 , N 2 , N 4 and N 5 , in the optimized steric structure thereof, are the interatomic distances in a pharmacophore; or a salt thereof; inhibits the activity of transcription factor AP-1 and is useful as an agent for preventing and treating the diseases into which overexpression of AP-1 participates and as an AP-1 inhibitor.

  该化合物由与N3对应的原子和从N1、N2、N4和N5中选择的两个或更多原子组成，这些原子构成了以下公式所代表的药效团：其中，N1代表氢键供体基团中的给氢原子所结合的原子或氢键受体基团中的接受氢原子的原子；N3代表氢键受体基团中的接受氢原子的原子；N2、N4和N5分别独立地表示构成疏水基团的任意碳原子，并由N1、N2、N3、N4和N5之间的原子间距离定义；在其优化的三维结构中，N3对应的原子与从N1、N2、N4和N5中选择的两个或更多原子之间的距离，在其优化的立体结构中，是药效团中的原子间距离；或其盐；抑制转录因子AP-1的活性，并且作为预防和治疗过度表达AP-1参与的疾病和AP-1抑制剂的制剂是有用的。
• COMPOSITIONS AND USES THEREOF IN THE TREATMENT OF WOUNDS
  申请人：Phylogica Limited

  公开号：EP2079526A1

  公开（公告）日：2009-07-22
• COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND CLINICAL DISORDERS ASSOCIATED WITH THEREWITH
  申请人：Phylogica Limited

  公开号：EP2170932A1

  公开（公告）日：2010-04-07
• Compositions and uses thereof for the treatment of wounds
  申请人：Fear Mark

  公开号：US20100166835A1

  公开（公告）日：2010-07-01

  The present invention provides a topical composition comprising (i) an amount of an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and/or necrosis induced by dermal wounding and/or to induce and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient e.g., a topical carrier or excipient or other carrier or excipient for dermal application. For example, the AP-1 signaling inhibitor is a peptide analog comprising the sequence set forth in SEQ ID NO: 104. The present invention also provides a method of treating a dermal wound comprising topically administering said topical composition to a subject suffering from a dermal wound.
• REGULATION OF MUTANT TERT BY BRAF V600E/MAP KINASE PATHWAY THROUGH FOS/GABP IN HUMAN CANCER
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20200323805A1

  公开（公告）日：2020-10-15

  The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for the treatment of cancer characterized by TERT and BRAF mutations. In a specific embodiment, a method for treating a mutant telomerase reverse trancriptase (TERT) enzyme-associated cancer in a subject comprises the step of administering to the subject an anti-cancer agent that inhibits one or more of FOS, GABPB, the formation of the GABPA-GABPB complex or the binding of the GABPA-GABPB complex to a mutant TERT promoter.